NCT06376565 Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
| NCT ID | NCT06376565 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jonsson Comprehensive Cancer Center |
| Condition | Colorectal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,680 participants |
| Start Date | 2023-11-08 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,680 participants in total. It began in 2023-11-08 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial tests a multilevel intervention at the clinic, provider and patient levels, to improve colonoscopy surveillance in patients with high risk colon polyps. Colorectal cancer (CRC) is a common and deadly disease that is largely preventable through the detection and removal of colorectal polyps. One million Americans are diagnosed with high risk polyps of the colon or rectum annually and are at increased risk for CRC; however, uptake of recommended repeat colonoscopy in 3 years to reduce CRC risk is low in this group. This multilevel intervention may work to improve timely colonoscopy screening for patients with high risk colon polyps.
Eligibility Criteria
Inclusion Criteria: * AIM 1 PATIENTS: Patients between age 45 and 75 with a HRN diagnosis in the past 5 years * AIM 1 PATIENTS: 12 patients who did and 12 patients who did not have surveillance colonoscopy * AIM 1 PROVIDERS: Primary care providers (PCPs) and gastroenterologists (GIs) * AIM 1 ADMINISTRATORS: Administrators who are involved in care processes related to CRC screening, HRN surveillance, and/or colonoscopy scheduling * AIM 2: Patients age 45 to 75 diagnosed with a HRN during the pre-specified two-year HRN diagnosis period Exclusion Criteria: * AIM 2: Individuals with a personal history of colorectal carcinoma (CRC), inflammatory bowel disease (Crohn's, ulcerative colitis), or polyposis syndrome * AIM 2: HRN cases not confirmed by chart review (human-in-the-loop)
Contact & Investigator
Folasade P May
PRINCIPAL INVESTIGATOR
UCLA / Jonsson Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06376565 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Colorectal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06376565 currently recruiting?
Yes, NCT06376565 is actively recruiting participants. Contact the research team at JCAlarcon@mednet.ucla.edu for enrollment information.
Where is the NCT06376565 trial being conducted?
This trial is being conducted at Los Angeles, United States.
Who is sponsoring the NCT06376565 clinical trial?
NCT06376565 is sponsored by Jonsson Comprehensive Cancer Center. The principal investigator is Folasade P May at UCLA / Jonsson Comprehensive Cancer Center. The trial plans to enroll 1,680 participants.